MTOR and prostate carcinoma: The activation of PI3K–AKT via p38–MAPK signaling promotes mTOR activation in pre-senescent prostate cancer cells, as well as in senescent cancer cells induced by chemotherapy or radiation treatment, thereby suppressing its negative activity against NF-κB.